Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  ABBOTT LABORATORIES
 2. Date of Event Requiring Statement (Month/Day/Year)
12/30/2016		 3. Issuer Name and Ticker or Trading Symbol
AquaBounty Technologies, Inc. [AQB]
(Last)
(First)
(Middle)
, 		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

,  		 6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock , par value $0.001 per share 22,130,040
I
Through CFR International SpA and Western Pharmaceuticals SA.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
ABBOTT LABORATORIES

 		     X    
CFR International SpA
100 ABBOTT PARK ROAD
AP6A-2, D-032L
ABBOTT PARK, IL 60064-6092		     X    

Signatures

Brian B. Yoor, By John A. Berry, Attorney-in-Fact. 12/30/2016
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
 
Remarks:
A total of 21,818,118 shares of Common Stock of AquaBounty Technologies, Inc. ("AquaBounty") described in this report are held directly by CFR International SpA ("CFR International"). CFR International is an indirect, wholly-owned subsidiary of Abbott Laboratories ("Abbott"). In Abbott's capacity as the ultimate corporate parent of CFR International, Abbott may be deemed to indirectly beneficially own such shares for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Securities and Exchange Commission thereunder. Western Pharmaceuticals SA, an indirect, wholly-owned subsidiary of Abbott ("Western Pharmaceuticals"), holds an additional 311,922 shares of Common Stock of AquaBounty.  Western Pharmaceuticals is subject to liquidation proceedings and voting and dispositive control over such shares is exercised by a liquidator appointed pursuant to Ecuadoran law.  For purposes of this report, such shares have been included in the shares of Common Stock reported as indirectly owned by Abbott. Exhibit List - Exhibit 24.1 - Powers of Attorney.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.